NASDAQ$CERS
Cerus Corp · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Cerus reported second quarter 2023 financial results.
Cerus Corporation reported a total revenue of $47.7 million for Q2 2023, consisting of $38.9 million in product revenue and $8.9 million in government contract revenue. The company is adjusting its full-year 2023 annual product revenue guidance to the range of $160 million to $165 million.
- Total revenue for Q2 2023 was $47.7 million, including $38.9 million from product revenue and $8.9 million from government contracts.
- Positive feedback received for INTERCEPT Red Blood Cells CE Mark submission, supporting possible CE Mark approval in the second half of 2024.
- Phase 3 ReCePI study enrollment completion planned this year, with top-line data expected in Q1 2024.
- Awarded an additional $8.7 million from the U.S. Department of Defense for LyoIFC development, increasing total contract value to $17.8 million.
Headline financials
Revenue & EPS history
Cerus · Revenue · Quarterly
$38.9M
Revenue by segment
Cerus · $47.7M total across 2 segments · Q2 2023
- Product Revenue$38.9M-5.2%81.4%
- Government Contract Revenue$8.88M+33.8%18.6%
Forward guidance
The Company expects full-year 2023 product revenue to be in the range of $160 million to $165 million.
Tailwinds
- Potential CE Mark approval decision in the second half of 2024.
- Top-line data readout from the U.S. Phase 3 ReCePI study expected in the first quarter of next year.
- Plan to begin a modular premarket approval (PMA) application submission to FDA in the second half of 2025.
- Final PMA module submission planned for the second half of 2026.
- New customers and new geographies will fuel growth going forward.
Headwinds
- Adjusting full-year 2023 annual product revenue guidance to the range of $160 million to $165 million from the prior range of $165 million to $170 million.
- Expected impact of a temporary reduction in U.S. platelet kit shelf life on customer ordering patterns.
- Reduced platelet collections in key regions of EMEA.
- New Russia sanctions.
- Restructuring plan will result in annualized operating expense savings of approximately $10 million per year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
-0.4%
Avg return
Earnings day
+1.0%
Avg return
5 days after
-0.8%
Avg return
30 days after
48%
31 / 65 earnings
Positive
+27.5%
Q3 2017
Best reaction
-19.6%
Q1 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.7% | +34.9% | +58.3% | |
| Q4 2025 | -17.3% | -23.7% | -26.5% | |
| Q3 2025 | -2.8% | +0.0% | +21.4% | |
| Q2 2025 | +0.8% | -2.3% | +3.9% | |
| Q1 2025 | +2.3% | +0.0% | -2.3% | |
| Q4 2024 | -5.2% | -5.7% | -12.1% | |
| Q3 2024 | -7.6% | -8.2% | +8.8% | |
| Q1 2024 | -5.8% | +7.6% | +4.1% | |
| Q4 2023 | +14.2% | +6.6% | -10.8% | |
| Q3 2023 | +25.4% | +25.4% | +21.0% | |
| Q2 2023 | -17.8% | -26.3% | -35.4% | |
| Q1 2023 | -0.9% | -6.1% | -1.7% | |
| Q4 2022 | -7.0% | +2.1% | -1.4% | |
| Q3 2022 | +7.7% | +6.0% | +18.9% | |
| Q2 2022 | -4.5% | -12.7% | -32.8% | |
| Q1 2022 | +2.9% | -2.7% | -2.3% | |
| Q4 2021 | -2.1% | +8.6% | +3.6% | |
| Q3 2021 | +14.5% | +16.0% | +1.5% | |
| Q2 2021 | +21.1% | +21.9% | +28.2% | |
| Q1 2021 | +2.7% | +4.8% | -7.7% | |
| Q4 2020 | -8.6% | -3.9% | -11.3% | |
| Q3 2020 | -5.4% | -0.4% | +18.6% | |
| Q2 2020 | -1.8% | -4.7% | -17.7% | |
| Q1 2020 | +2.1% | +5.2% | +12.5% | |
| Q4 2019 | -1.0% | -6.0% | -39.2% | |
| Q3 2019 | -4.4% | -3.7% | -4.6% | |
| Q2 2019 | -8.7% | -13.5% | -8.2% | |
| Q1 2019 | -12.3% | -15.2% | -27.3% | |
| Q4 2018 | +2.8% | +6.5% | -3.7% | |
| Q3 2018 | -4.9% | -13.4% | -21.6% | |
| Q2 2018 | -5.9% | -4.8% | +4.1% | |
| Q1 2018 | +11.9% | +17.1% | +17.8% | |
| Q4 2017 | +2.1% | +7.5% | +9.0% | |
| Q3 2017 | +27.5% | +26.4% | +40.9% | |
| Q2 2017 | +3.6% | +7.1% | +6.7% | |
| Q1 2017 | -19.6% | -28.3% | -44.5% | |
| Q4 2016 | -7.8% | +5.0% | +0.7% | |
| Q3 2016 | +6.4% | +15.0% | +10.2% | |
| Q2 2016 | +1.8% | -4.5% | -11.3% | |
| Q1 2016 | -6.6% | — | — | |
| Q4 2015 | +0.5% | — | — | |
| Q3 2015 | +4.5% | — | — | |
| Q2 2015 | -2.5% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | -12.7% | — | — | |
| Q3 2014 | -5.8% | — | — | |
| Q2 2014 | +4.8% | — | — | |
| Q1 2014 | +4.4% | — | — | |
| Q4 2013 | -15.7% | — | — | |
| Q3 2013 | -6.1% | — | — | |
| Q2 2013 | +6.7% | — | — | |
| Q1 2013 | -9.7% | — | — | |
| Q4 2012 | +14.0% | — | — | |
| Q3 2012 | -1.9% | — | — | |
| Q2 2012 | -2.7% | — | — | |
| Q1 2011 | +0.5% | — | — | |
| Q1 2012 | +1.5% | — | — | |
| Q4 2009 | +0.8% | — | — | |
| Q4 2011 | +0.8% | — | — | |
| Q3 2010 | +1.4% | — | — | |
| Q3 2011 | +1.4% | — | — | |
| Q2 2010 | -2.8% | — | — | |
| Q2 2011 | -2.8% | — | — | |
| Q4 2010 | -2.8% | — | — | |
| Q1 2010 | -2.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro